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INTRODUCTORY NOTE 
Precision is an imperative in modern radiotherapy. This concept is applied in a day-to-day 
basis at all levels in planning and delivering treatment to patients, since only by uniting all 
these aspects is it’s real application possible. 
Given that I am a radiation technologist in an institution where the purpose is to ensure 
accuracy in administered treatment, my main focus was to direct this work towards the field 
in which I dwell daily. Indeed, making sure that all instruments available have a precisely 
studied role in the quality of the execution of prescribed treatment has become a necessity 
that justifies the enormous amount of care put in the treatment phase in radiotherapy. This 
applies, namely, to the recently-implemented cone-beam computed tomography (CBCT) tool.  
Therefore, computerized tomography dose indices (CTDI) were acquired in order to monitor 
doses administered to patients through CBCT. This was followed by the selection of twenty 
one patients of pathologies involving a great amount of precision: fourteen patients with 
prostate and seven patients with head and neck tumours. This sample was characterized 
with the acquisition of CBCT pre and post-treatment, as well as after any correction 
performed on their positioning. This allowed for evaluating intra-fraction errors. 
From within this sample, patients out of action limits were chosen, as analyzed in control 
charts for mean and standard deviation of their positioning deviations, as well as patients out 
of tolerance limits for deviation correction. 
Finally, new dosimetric distributions were performed, in which the isocenter accounts for the 
measured positioning errors. The doses in organs at risk and eventual differences in 
planning target volume (PTV) coverage with 95% of the dose between these and the planned 
distributions were compared for each of these patients. This simulation allowed for inferring 
what would have happened had these errors not been accounted for and corrected. 
This study also evaluated the feasibility of using CBCT in the imaging verification during the 
treatment of patients with the aforementioned pathologies, as well as the adequacy of the 
image acquisition protocol, as currently implemented at the department. The evaluation and 
quantification of systematic and random translational and rotational errors was also made 
possible, as defined by current departmental practices. This allowed for adapting not only the 
mentioned protocol, but also margins currently added to clinical target volumes (CTV) for 
PTV generation. This will allow to ensure that protocols are based on data obtained locally, 
which will undoubtedly procure better results in cancer healthcare at the department. 
It is noteworthy that the Master Comission authorized the presentation of this work as a 
scientific article, with the purpose of future publication in international, peer-reviewed 
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journals. In order to do so, it is not only written in English, but it also respects criteria related 
to this objective.  
In the first part, a review on state-of-the-art literature is rendered (previously submitted in 
May 2011, even though some aspects have been corrected or updated), as to allow for a 
contextualization of my work. The feasibility of the IGRT protocol, as implemented at my 
department, is then assessed. Finally, as previously discussed, systematic and random 
translational and rotational errors are evaluated. 
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RESUMO 
INTRODUÇÃO: Numa era em que os tratamentos de Radioterapia Externa (RTE) exigem cada vez mais 
precisão, a utilização de imagem médica permitirá medir, quantificar e avaliar o impacto do erro 
provocado pela execução do tratamento ou pelos movimentos dos órgãos. OBJECTIVO: Analisar os 
dados existentes na literatura acerca de desvios de posicionamento (DP) em patologias de Cabeça e 
Pescoço (CP) e próstata, medidos com Cone Beam Computed Tomography (CBCT) ou Electronic 
Portal Image Device (EPID). METODOLOGIA: Para esta revisão da literatura foram pesquisados artigos 
recorrendo às bases de dados Medline/Pubmed e B-on. Foram incluídos artigos que reportassem DP 
em patologias CP e próstata medidos através de CBCT e EPID. Seguidamente foram aplicados 
critérios de validação, que permitiram a selecção dos estudos. RESULTADOS: Após a análise de 35 
artigos foram incluídos 13 estudos e validados 9 estudos. Para tumores CP a média (μ) dos DP 
encontra-se entre 0,0 e 1,2 mm, com um desvio padrão (σ) máximo de 1,3mm. Para patologias de 
próstata observa-se μDP compreendido entre 0,0 e 7,1 mm, com σ máximo de 7,5mm. DISCUSSÃO/ 
CONCLUSÃO: Os DP em patologias CP são atribuídos, maioritariamente, aos efeitos secundários da 
RTE, como mucosite e dor, que afectam a deglutição e conduzem ao emagrecimento, contribuindo 
para a instabilidade da posição do doente durante o tratamento, aumentando as incertezas de 
posicionamento. Os movimentos da próstata devem-se principalmente às variações de 
preenchimento vesical, rectal e gás intestinal. O desconhecimento dos DP afecta negativamente a 
precisão da RTE. É importante detectá-los e quantificá-los para calcular margens adequadas e a 
magnitude dos erros, aumentando a precisão da administração de RTE, incluindo o aumento da 
segurança do doente.  
PALAVRAS CHAVE: Desvios de posicionamento, Cone-Beam CT, EPID, Precisão. 
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ABSTRACT: 
BACKGROUND AND PURPOSE: In an era where precision is an increasing necessity in external 
radiotherapy (RT), modern medical imaging techniques provide means for measuring, quantifying and 
evaluating the impact of treatment execution and movement error. The aim of this paper is to review 
the current literature on the quantification of setup deviations (SD) in patients with head and neck 
(H&N) or prostate tumors, using Cone Beam Computed Tomography (CBCT) or Electronic Portal 
Image Device (EPID). METHODS: According to the study protocol, Medline/Pubmed and B-on 
databases were searched for trials, which were analyzed using selection criteria based on the quality 
of the articles. RESULTS: After assessment of 35 papers, 13 studies were included in this analysis and 
nine were authenticated (6 for prostate and 3 for H&N tumors). The SD in the treatment of H&N 
cancer patients is in the interval of 0.1 to 1.2 mm, whereas in prostate cancer this interval is 0.0 to 7.1 
mm. DISCUSSION: The reproducibility of patient positioning is the biggest barrier for higher precision in 
RT, which is affected by geometrical uncertainty, positioning errors and inter or intra-fraction organ 
movement. There are random and systematic errors associated to patient positioning, introduced 
since the treatment planning phase or through physiological organ movement. CONCLUSION: The H&N 
SD are mostly assigned to the Radiotherapy adverse effects, like mucositis and pain, which affect 
swallowing and decrease secretions, contributing for the instability of patient positioning during RT 
treatment and increasing positioning uncertainties. Prostate motion is mainly related to the variation in  
bladder and rectal filling. Ignoring SD affects negatively the accuracy of RT. Therefore, detection and 
quantification of SD is crucial in order to calculate appropriate margins, the magnitude of error and to 
improve accuracy in RTE and patient safety. 
 
KEYWORDS: Set-up deviation, Cone-Beam CT, EPID, Accuracy. 
 
1. INTRODUÇÃO 
O objectivo primordial da Radioterapia Externa (RTE) é a administração de uma 
dose de radiação, medida com precisão, num volume tumoral definido, com o 
mínimo possível de efeitos secundários nas células vizinhas. Com este método de 
tratamento, pretende-se a erradicação do tumor, elevada qualidade de vida e 
prolongamento da sobrevivência.1 
De maneira a tornar este objectivo real e exequível, com o menor número de 
imprecisões, foram definidas incertezas e fontes de erro em RTE associadas à 
preparação e administração do tratamento. Sabe-se, então, que as fontes de 
introdução de incertezas estão principalmente relacionadas com incertezas de 
posicionamento do doente, assim como com a delimitação do Gross Tumor Volume 
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(GTV), devendo-se esta última ao desconhecimento da extensão microscópica do 
tumor. 2-8,10 
Centrar-nos-emos, neste trabalho, na análise das incertezas de posicionamento, 
nomeadamente dos desvios de posicionamento (DP) do doente durante o 
tratamento de radioterapia. São estes definidos como diferenças anatómicas 
observáveis através da comparação de uma imagem de referência com uma 
imagem prévia ao tratamento.10-13 
Atendendo à dimensão desta problemática e centrando-nos numa Era em que a 
precisão é cada vez mais exigida, a utilização de imagem médica permitirá medir, 
quantificar e avaliar o impacto dos DP na execução do tratamento ou no erro 
provocado pelos movimentos dos órgãos de uma forma mais precisa. Nesse sentido, 
tem-se verificado, nas últimas décadas, um claro aumento do investimento na 
tecnologia utilizada nesta área. Tornou-se assim comum a introdução de protocolos 
de verificação imagiológica com recurso a ferramentas como o Electronic Portal 
Image Device (EPID) ou a Cone Beam Computed Tomography (CBCT) nos 
departamentos de radioterapia a nível mundial.   
A utilização de EPID para verificação do posicionamento do doente revelou-se 
um método eficaz, substituindo a utilização de filmes radiográficos em Radioterapia. 
Tal, deve-se, ao facto de estas imagens digitais, obtidas através de um detector de 
silício amorfo, terem um maior contraste e uma qualidade marcadamente superior. 
Ao recorrermos a este método, os DP são baseados, principalmente, na anatomia 
óssea, facilmente observada em duas dimensões (2D).14 
Com o intuito de aumentar a precisão da Radioterapia, surge o CBCT, com a 
possibilidade de realizar imagens volumétricas, associadas a uma boa visualização 
de tecidos moles, baixas doses de radiação e possibilidade de observar variações 
inter e intrafracção.15 Este sistema é baseado numa fonte de raios x posicionada no 
sentido oposto do detector, posicionada no anel do acelerador linear. Enquanto a 
gantry roda à volta do doente, a reconstrução da imagem é obtida através de uma 
aproximação bidimensional dos dados de projecção.3  
Tendo em conta esta realidade, o presente trabalho pretende analisar a literatura 
existente acerca de DP em doentes com patologias de Cabeça e Pescoço (CP) e 
próstata, medidos com CBCT ou EPID. 
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2. METODOLOGIA 
 
2.1 PESQUISA DE ARTIGOS 
Para esta revisão de literatura foram pesquisados artigos recorrendo às bases de 
dados Medline/Pubmed e B-On, através das palavras Cone-Beam CT, EPID, Head 
and Neck, Prostate, Intrafraction errors, intrafraction errors e setup error. A pesquisa 
foi limitada a publicações escritas em Inglês. 
 
 
Tabela 1: Parâmetros de validação dos estudos incluídos. 
 
 
 
 
Parâmetros de avaliação dos estudos Classificação 
1. Materiais e métodos explicados 5 
2. Dados dos desvios disponíveis: 
a) Dados em bruto 
b) Média, desvio padrão, medida de tendência central 
 
3 
2 
3.  Descrição da metodologia de análise dos DP e erros aleatórios e 
sistemáticos  
3 
4. Avaliação dos erros de setup segundo um protocolo de aquisição de 
imagem 
2 
5. Dimensão da amostra: 
 
a) 6 a 10 doentes 
b) 11 ou mais doentes 
 
 
2 
3 
6. Conformidade entre objectivo e métodos utilizados 5 
7. São quantificados DP? 5 
8. Existe análise dos desvios de posicionamento? 5 
9. É apresentado um significado clínico para os DP? 5 
10. É um estudo prospectivo? 5 
11. A conclusão está em conformidade com o objectivo proposto? 5 
12. São sugeridas estratégias para diminuição do erro sistemático? 3 
13. Um dos objectivos é definição de protocolo ou linhas de orientação para 
implementação? 
3 
14. Existe uma preparação prévia ao tratamento? 4 
15. Descrição da preparação, se aplicável. 3 
16. Uniformidade do posicionamento dos doentes. 2 
17. Consentimento informado 1 
Classificação máxima: 62 
16 
 
2.2 SELECÇÃO DE ARTIGOS  
Foram incluídos artigos que quantificassem DP de doentes com tumores 
malignos de próstata ou localizados na região de CP submetidos a tratamentos RTE. 
Destes, foram seleccionados os estudos cujos DP foram avaliados através das 
ferramentas de aquisição de imagem CBCT ou EPID.  
Em alguns dos estudos foram apenas seleccionados os dados referentes às 
patologias de próstata e patologias de CP, sendo excluídos todos os DP existentes 
referentes a outras patologias. 
 
Autor Ano Posicionamento Amostra 
Ferramenta 
de aquisição 
de imagem  
Xu et al
21
 2008 
Dec. Dorsal; Acessório de fixação de 
mascaras; máscara termoplástica de 
cabeça; depressor de ombros; apoio 
popliteu. 
n=19 CBCT 
Wang et al
23
 2009 
Dec. Dorsal; Acessório de fixação de 
mascaras; máscara termoplástica de 
cabeça; apoio popliteu. 
n=22 CBCT 
Xu et al
22
 2009 
Dec. Dorsal; Acessório de fixação de 
mascaras; máscara termoplástica de 
cabeça; depressor de ombros; apoio 
popliteu. 
n=19 CBCT 
 
Tabela 2 : Representação por autor, ano, posicionamento, ferramenta de aquisição de imagem dos estudos de 
patologias de CP considerados para este trabalho. 
 
2.3 ESTRATÉGIAS DE SELECÇÃO DE ARTIGOS 
Para a presente revisão, foram definidos parâmetros de avaliação da qualidade 
dos estudos incluídos, tal como descritos por Jadad et al.17 
Elaborou-se uma tabela (tabela1) com os itens considerados como 
desejavelmente descritos nos artigos. De seguida, foi verificada a conformidade 
entre os parâmetros definidos e os descritos nos estudos. Caso os itens estivessem  
descritos, seria atribuída a classificação designada. A classificação máxima 
estimada para os artigos incluídos foi de 62 pontos. Foram excluídos todos os 
estudos que obtiveram uma classificação inferior ou igual a 29 pontos, cujos dados 
de DP não estivessem quantificados e cuja amostra fosse inferior a 5 doentes.  
Após terem sido incluídos 13 estudos para esta revisão foram validados 9 estudos (3 
referentes a tumores de CP e 6 a patologias de próstata). A pontuação média obtida 
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no processo de validação dos estudos foi de 39,1 pontos, com amplitude de 31 a 49 
pontos.  
Na tabela 2 e 3 encontram-se descritos os estudos e algumas das suas 
características.  
 
Tabela 3 : Representação por autor, ano, posicionamento, dimensão da amostra, marcadores fiduciais, 
preparação e ferramenta de aquisição de imagem dos estudos de patologias de próstata considerados. 
 
3. RESULTADOS  
 
3.1. DESVIOS DE POSICIONAMENTO 
3.1.1. CABEÇA E PESCOÇO 
Na tabela 4 encontram-se descritos os resultados, da média (µDP) e desvio 
padrão (σDP) dos DP dos mesmos autores. Wang et al. documentaram que a µDP se 
encontrava entre 0,0 e 0,7 mm, enquanto o intervalo de σDP é de 0,4 a 1,3 mm. Xu et 
al. registou, em 2008, valores de µDP entre 0,6 e 1,2 mm com σDP entre 0,5 e 1,1mm. 
Em 2009, o mesmo autor publicou um estudo cujos doentes apresentavam DP entre 
0,1 e 0,3 mm, com σ entre 0,4 e 0,8 mm. 
Nairz et al.
26 
2008 Não especificado n=27 Não Não CBCT 
Aubry et al.
29 
2004 Não especificado 
 
n=18 
Sim 
Bexiga Cheia 
e recto vazio 
EPID 
Sandhu et 
al.
27 2008 
Dec. Dorsal; 
colchão de vácuo. 
n=26 Sim 
Bexiga Cheia 
e recto vazio 
EPID 
Polat et al.
28 
2008 Não especificado n=27 Não 
Bexiga Cheia 
e recto Vazio. 
Aconselhame
nto 
nutricional. 
CBCT 
Chueng et 
al.
30 2005 
Dec. Dorsal; 
colchão de vácuo. 
n=33 Sim 
Bexiga e recto 
vazios 
EPID 
Rajendran et 
al.
31 2010 
Dec. Dorsal; apoio 
região pélvica e 
região politeia 
n=28 Sim Bexiga cheia EPID 
18 
 
 
Tabela 4: Representação dos DP (média ± desvio padrão) para patologias de CP.X,Y e Z, representam, 
respectivamente, os sentidos latero-medial, crânio-caudal e antero-posterior. 
 
3.1.2. PRÓSTATA 
Na tabela 5 encontram-se descritos os resultados dos autores. Nairz et al. 
documentaram que o µDP se encontrava entre 0,0 e 0,7 mm, enquanto o intervalo de 
σDP é de 1,6 a 3,4 mm. Aubry et al. registou valores de µDP entre 0,0 e 0,2 mm com 
σDP entre 0,2 e 0,7mm. Sandhu et al publicou DP entre 1,0 e 5,3 mm, com σDP entre 
1,7 e 8,1 mm. Polat et al. analisou, apenas, os DP no sentido antero-posterior, e foi 
obtida µDP=0 mm, para todas as aquisições, os valores de σDP encontraram-se entre 
1,0 e 1,7mm, enquanto que para Cheung et al., a média dos DP foi quantificada 
entre 0,14 e 0,72mm. Rajendram et al. registou um µDP entre 0,7 mm e 7,1mm.  
Os valores mais elevados de DP, para estas patologias encontram-se no sentido 
antero-posterior.  
4. DISCUSSÃO 
A reprodutibilidade do posicionamento do doente é a maior barreira para o 
aumento da precisão em Radioterapia, que é afectada por múltiplos aspectos 
inerentes ao tratamento.13,24,25 Nesse sentido, caracterizam-se os DP como o 
somatório de erros sistemáticos (introduzidos ao longo do planeamento), erros 
aleatórios (associados a cada fracção) e de incertezas geométricas (relacionadas 
com o equipamento).6 
Para CP, observa-se que a média dos DP tem uma amplitude entre 0,0 e 1,2 
mm, com um desvio padrão máximo de 1,3 mm. É ainda de referir que os resultados 
dos não diferem significativamente na literatura consultada, o que poderá ser 
atribuído à utilização de máscara de imobilização. Nestes estudos, o aumento dos  
AUTOR 
DP (MÉDIA ± DESVIO PADRÃO) 
SENTIDOS 
Latero-medial 
(X) 
Cranio-caudal 
(Y)  
Antero-Posterior (Z)  
Wang et al.
23
 
-0,7±1,1 
-0,4±0,5 
-0,3±0,7 
-0,7±1,3 
0,3±0,5 
0,3±0,9 
-0,3±1,2 
0,0±0,4 
0,1±0,7 
Xu et al.
22
 
-0,3±0,5 
-0,3±0,6 
0,1±0,5 
0,3±0,8 
0,2±0,4 
0,2±0,6 
Xu et al.
21 
1,2±0,9 
1,2±1,1 
1,0±0,8 
0,7±0,6 
0,6±0,5 
0,6±0,5 
0,9±0,8 
1,0±0,9 
0,9±0,7 
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Tabela 5: Representação dos DP(média ± desvio padrão), em mm, para patologias de Próstata. X,Y e Z, 
representam, respectivamente, os sentidos latero-medial, crânio-caudal e antero-posterior. 
 
DP no decorrer da RTE é relacionado com o aparecimento de efeitos secundários do 
tratamento, nomeadamente mucosite e xerostomia. De facto, com o aparecimento 
destes sintomas, a deglutição é afectada, conduzindo a perda ponderal. Se 
somarmos a este factor a dor inerente ao desenvolvimento de inflamação nos 
tecidos durante o tratamento, compreende-se que o posicionamento do doente sofre 
de uma maior imprecisão e menor reprodutibilidade. 21-23  
Nesta análise verifica-se que os DP em doentes com patologia de CP são 
menores do que no caso de doentes com patologia prostática. No entanto, não 
devemos descurar o seu estudo e medição, já que existem valores atípicos para 
alguns doentes que deverão sempre ser corrigidos. 
Os DP da próstata devem-se principalmente a variações de preenchimento 
vesical e rectal. Observa-se que a média dos DP para próstata tem uma amplitude 
de 0,0 e 7,1 mm, com um desvio padrão máximo de 7,5mm. Os menores valores de 
DP são reportados por Polat et al., apresentando-se no sentido antero-posterior. Tal 
poderá estar relacionado com o facto de o aconselhamento nutricional, aplicado por 
estes autores, ser um factor essencial para o controlo da posição do recto e, 
consequentemente, da próstata. É assim realçada a importância da implementação 
de um protocolo que englobe esta componente, além da necessária preparação de 
bexiga e recto. Note-se que apenas um autor desconsiderou a preparação rectal e 
vesical.26 
Autor 
DP (média±desvio padrão) 
S.Latero-Medial (X) S. Craneo-caudal (Y) S.Antero-posterior (Z) 
Nairz et al.
26 
0,0±1,6 0,0±2,4 0,7±3,4 
Aubry et al.
29 
0,2±0,2 0,0±0,4 0,2±0,7 
Sandhu et al.
27 
3,9±5,9 
1,0±1,7 
3,6±5,6 
5,3±8,1 
2,4±2,1 
4,9±7,5 
3,8 ±5,5 
2,8±2,1 
5,2±7,1 
Polat et al.
28 
Não foi avaliado Não foi avaliado 
0±1,7 
0±1,0 
0±1,3 
Chueng et al.
30 
0,14±0,9 0,45±1,3 0,72±1,8 
Rajendran et al.
31 
0,8±6,8 4,2±4,9 7,1±7,4 
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É ainda de referir que não existe unanimidade na literatura em relação ao 
procedimento que deverá ser realizado para controlar o volume da bexiga. Alguns 
autores referem instruir os doentes para ingerir sempre a mesma quantidade de 
água antes do tratamento. Contudo, na maioria dos artigos analisados não é descrita 
a quantidade de água nem o tempo de espera antes de realizar tratamento. Por 
outro lado, Chueng et al. defendem que a bexiga e o recto deverão estar vazios 
antes do tratamento para que se possa controlar o movimento interno da próstata de 
uma forma precisa.  
Verifica-se ainda que os autores que utilizam CBCT não colocam marcas 
radiopacas na próstata, apesar de não ser referida uma justificação. Sugere-se que 
o motivo desta observação se prende com a visualização de tecidos moles nas 
imagens de CBCT. Apesar da visualização da próstata se manter inexacta ao 
recorrer a tomografia computorizada, é muito mais precisa quando comparada com 
EPID, onde apenas são visíveis estruturas ósseas. É ainda de referir que os quatro 
autores analisados que utilizam EPID, recorrem à utilização de marcadores fiduciais. 
Os DP apresentados nos estudos que contemplam a patologia de próstata 
poderão não ser comparáveis, uma vez que se verificam diferenças no 
posicionamento utilizado para os doentes de próstata entre os diversos autores. 
 
5. CONCLUSÃO 
O desconhecimento dos DP afecta negativamente a precisão da radioterapia, 
pelo que a detecção e quantificação dos primeiros permitirá o aumento da última. De 
facto, conhecer o DP para cada patologia em cada centro de Radioterapia permitirá 
calcular o erro sistemático e aleatório associado à localização de tratamento. Tal 
permitirá não só calcular margens de tratamento adequadas, mas também definir 
protocolos de aquisição de imagem. Esta abordagem levará a um incremento da 
precisão e diminuição das incertezas no tratamento. Aumentar-se-á, 
consequentemente, a sua qualidade de administração.  
Verifica-se existirem mais estratégias de redução de DP para a patologia de 
próstata do que para CP. Esta diferença decorrerá potencialmente dos valores de 
DP documentados para CP serem relativamente diminutos quando comparados com 
os DP de patologias próstaticas. No entanto, entende-se que para CP é desejável o 
desenvolvimento de estratégias que minimizem a toxicidade da RTE. Tal como 
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anteriormente referido, a toxicidade do tratamento provoca queixas álgicas e 
evolução da morfologia (com a perda ponderal) do doente, tornando-a, segundo os 
autores, na maior fonte de DP durante o tratamento.  
Verificam-se, presentemente, grandes discrepâncias na forma de apresentar 
estes resultados na literatura. Futuramente dever-se-ão definir linhas de orientação 
que permitam uma definição uniforme e inequívoca de como quantificar DP com os 
vários métodos disponíveis. Deverão ser sempre tomados em conta aspectos como 
a ferramenta de imagem usada, os momentos da sua utilização, a definição de um 
eventual protocolo nutricional e/ou de preparação de órgãos de risco e o método de 
análise dos vários parâmetros. A instituição de uma homogeneização dos dados 
publicados permitiria, no futuro, análises metodológicas mais claras e a potenciação 
do desenvolvimento de melhores estratégias no caminho para o aumento da 
precisão em radioterapia. 
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BACKGROUND/PURPOSE: Treatment accuracy and reproducibility are important issues in 
radiotherapy. In order to minimize uncertainties, implementation of Image-Guided 
Radiotherapy(IGRT) has become an imperative. This work is intended to discuss and assess 
the feasibility of an implemented IGRT protocol in a radiotherapy department, for prostate 
and Head ans Neck(HN) patients, with the use of Cone-Beam Computed 
Tomography(CBCT). 
MATERIAL/METHODS: Computed Tomography Dose Indices(CTDI) were measured in a 
phantom to preview the delivered doses with CBCT. A sample of 21 patients(pts) was then 
selected, composed of 14 pts with prostate and 7 pts with HN tumours. CBCT images were 
subsequently acquired from pts. Dose distributions were performed for 6 prostate and 6 head 
and neck pts, chosen according to setup deviation magnitude in control charts.  
RESULTS: The administered doses ranged from 9,18mGy to 15,76mGy for HN and from 
170,7mGy to 528,8mGy. Differences in Prostate PTV were:-40,3cc to 2,8cc for PTV1; -
22,3cc to -4cc for PTV2 and -8,1cc to -2,7cc for PTV3. For HN pts the differences in dose 
distributions ranged from -7,4cc to 3,3cc for PTV1 and from -5,1cc to 0.8 cc for PTV2. 
CONCLUSIONS: The IGRT protocol is feasible, safe and yields a clear therapeutic gain for 
pts with HN and prostate tumours. Future work should be aimed at accounting for the dose 
delivered with CBCT at the treatment planning level. 
ADVANCES IN KNOWLEDGE: A new evaluation method for IGRT protocol efficacy, that 
takes into account setup error corrections dosimetrically, is described. According to it, 
increased dose administered by CBCT is justified. 
 
INTRODUCTION 
 
With the emergence of new dose-delivering techniques in the 1990s, such as radiosurgery 
and Intensity Modulated Radiotherapy (IMRT), treatment accuracy and reproducibility in 
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Rdiotherapy (RT) became a crucial issue.[1-4] In order to minimize positioning uncertainties, 
previously described by several authors, implementation of imaging tools for treatment 
verification has become an imperative. [5-8] 
The utilisation of Imaged-guided Radiotherapy (IGRT) protocols has been precisely 
described in the literature in several instances, as has the use of imaging tools in the 
treatment room to evaluate and correct set-up deviation (SetD). One of these tools is the 
Cone Beam Computed Tomography (CBCT), which allows the tridimensional verification of 
patient anatomy, enabling visualization of the tumour and surrounding structures. It is thus 
possible to adjust patient positioning immediately before treatment, detecting gross errors, 
eliminating systematic errors and reducing random errors.[9-13] The implementation of an 
IGRT protocol, using CBCT, allows for a predicted increase in the clinical benefit of 
radiotherapy, since monitoring organ motion, verification of tumour volume movement, size 
and position, and control position error are thus made possible.[7,14-20] 
However, there is a foreseeable consequence: the administered dose is increased by image 
acquisition during treatment. The Report of the American Association of Physicists in 
Medicine (AAPM) Task Group 75 recommends that the risk of increasing dose has to be 
weighed against the eventual increase in precision during treatment delivery.[21] 
In accordance with this paradigm, the feasibility of the imaging verification protocol for 
prostate and head and neck tumours using CBCT, implemented at our department, is hereby 
analysed, we verify an eventual clinical benefit that, may, outweigh the aforementioned dose 
increment. In order to accomplish this purpose, Computed Tomography Dose Index (CTDI) 
values were measured in a phantom so as to preview the delivered doses with CBCT 
acquisition. CBCT images were subsequently acquired from patients. Doses distributions 
were then performed in a Treatment Planning System (TPS), taking into account the setup 
deviation (SetD) measured in patients, with the objective of simulating what would be the 
predictible scenario if the deviations had not been corrected.  
 
METHODS AND MATERIALS 
 
As aforementioned, the main objective of the work hereby reported was the evaluation of the 
feasibility of the IGRT protocol currently implemented at our department. CTDI 
measurements inherent to the acquisition of CBCT imaging were quantified for prostate and 
HN pathologies with the different filters and collimators of the Beam Modulator TM (ELEKTA 
Oncology Systems,Crawley, UK) linear accelerator. A sample of 21 patients 7 with HN and 
14 with prostate tumours) was subsequently selected. Pre-treatment imaging was acquired in 
accordance with the IGRT protocol, and by using control charts, pts with SetD out of statistic 
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control were identified. Dosimetric distributions were performed for the latter patients to 
evaluate the impact of the SetD in case these would not have been corrected. 
 
Kilovoltage X-ray IGRT system 
CTDI measurements were made in a Beam ModulatorTM (ELEKTA Oncology Systems, 
Crawley, UK) linear accelerator using CBCT protocols integrated into the X-Ray Volume 
Imaging (XVI®) software as described by several authors. [22-24] The XVI® system (release 
4.2.1) consists of a conventional x-ray tube mounted on a retractable arm and a kV detector 
planel, itself mounted on the drum of the digital accelerator. The tube was located 1000mm 
from the center of rotation and has 1,5mm Al equivalent inherent filtration and additional 
compound filtration of 2mm Al and 0,1mm Cu. The tube potentials ranged from 40kVp to 
130kVp. Exposures are pulsed and range from 0,1mAs to 500 mAs per X-ray projection. In 
the site opposite to the tube is located the amorphous silicon (AmSi) flat panel, which has an 
active area of 409,6x409,6mm and is located 536mm from the axis rotation.  
 
CTDI measurements 
CTDI measurements were performed in a phantom (Fluke Biomedical Model 76-414-4150) 
made of solid acrylic having a thickness of 15 cm and a diameter of 32 cm, in order to 
simulate the pelvis, or 16 cm, to simulate the head (Figure 1).These two phantoms contained 
five probe holes, one in the center and four around the perimeter, 90º apart from the center 
and 1cm from the edge. Each part includes five acrylic rods for plugging all the holes in the 
phantom. A 0,125cm3 ionization chamber (TM3009, PTW Freiburg) was used in this study 
(Nk= 8,342*10^6 Gy/C and Kq=1.0 were introduced in PTW webline electrometer).   
Measurements were made in the center and at four equal peripheral holes. For the pelvis, 
dose indices were acquired with 660 frames in full rotation (360º). The reconstructed 
diameter for this location was the medium field of view (FOV), corresponding to 410 mm. For 
the head, 361 frames were acquired with a 160º rotation and a small FOV, with 270 mm of 
diameter. In order to simulate the treatment setup for this location, the flat panel was shifted 
laterally to a corresponding asymmetric collimator. 
The Report of the AAPM Task Group 75 recommends CTDIw to be a weighted index, since it 
reflects the weighted average of dose deposition in the peripheral (p) and centrer (c) as in 
the relation (1): 
 
(1)     CTDIw=
 
    
      
 
 
      , in mGy. 
 
Figure 1: CTDI measurements for pelvis region (on the left) and Head region (on the right). 
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Patients 
Prostate and HN patients were randomly selected. This study included 14 prostate patients 
and 7 HN patients. Regardless of the treatment technique, all patients underwent an IGRT 
protocol for verification of patient setup and treatment delivery conditions. All patients had 
localized tumours, with no known metastases in other organs. The HN patients were 
diagnosed with tumours located in the tongue (n=2), in the oral cavity (n=2), in the glottis 
(n=1), in the parotid (n=1) and in the cheek mucosa (n=1). 
Prostate patients were instructed to urinate and drink 250mL of water 30 minutes before 
treatment. They were also told to empty their rectums 2 hours prior to each radiotherapy 
fraction. Nutritional support was provided, in order to allow for a diet without residue.   
All patients signed an informed consent. 
 
IGRT Protocol 
Each imagiologic verification comprised of an acquisition before treatment. A post-correction 
acquisition was carried out to confirm SetD corrections. 
The periodicity of acquisitions was consecutive for the first four fractions of treatment. A 
mean of the deviations from the three initial fractions was calculated, with the purpose of 
minimising systematic error and, thereafter, applied to the fourth treatment fraction. Weekly 
verifications were subsequently scheduled.  
Deviation corrections were performed according to the defined tolerance values (TL), which 
were 3 mm for HN in all axes and for all treatment phases. For the first phase of treatment of 
the prostate group, tolerance values were 5 mm in the latero-medial (LM) and in the cranio-
caudal (CC) axes, with 3 mm in the antero-posterior axis (AP). For the second and third 
treatment phases, tolerance values were defined, for the latter group, as 3 mm in all 
directions. 
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Setup deviation impact 
In order to select the patients whose SetD were out of statistical control and to evaluate 
process quality, control charts were constructed for the mean and standard deviations of the 
setup deviations observed in the LM, CC and AP axes. The upper and lower control limits 
(UCL and LCL, respectively) were built with the values of 3 standard deviations and TL, 
which were previously described. 
Patients with SetD out of the action limits and/or the TL on the control charts were selected 
from the sample of 21 patients. The analysis of the points in the control charts was restricted 
to points over or overlapping the control limits for mean and standard deviation (SD), since 
the established order of these points corresponds to each patient and not to a temporal 
observation.  
For evaluating the SetD impact dose distribution a method described by Takemura et al.[25] 
was adapted. Initial dose distributions (dose distribution 1), approved at the beginning of 
treatment, were copied for the selected patients and new dose distributions (dose distribution 
2) were carried out on the XIO® (CMS) TPS. The only difference applied to these new 
plannimetries was the isocenter location, in order to simulate SetD. 
For SetD simulation, treatment fields were copied. As an example, if we consider 3 corrected 
SetD and an implemented mean of the systematic error for the ensuing fractions of HN 
treatment, prescribed as 2 Gy in 25 fractions, the initially generated fields were copied 4 
times (the fields with the isocenter of the mean were prescribed with 22 fractions and the 
other 3 groups of fields with one fraction, corresponding to 3 corrected SetD). If SetD weren’t 
corrected during the 3 initial fractions, the mean was applied to all the subsequent fractions. 
In order to find the new isocenter that took the corrected SetD or mean into account, a sum 
of the SetD values was calculated and applied to the number of fractions in which they 
occurred. After this, monitor unit number was verified and adjusted, if necessary, to be 
exactly equal to the dosimetric distribution 1. Normalization points were also maintained.  
However, it became clear that the Multi Leaf Collimator (MLC) conformation was altered in 
the treatment planning system, when the isocenter coordinates were modified. In order to 
tackle this problem, the coordinates of each leaf pair was manually introduced for each field 
as to ensure that they would be in the exact same position of the initial plan. 
Lastly, dose-volume histograms (DVH) were generated and the differences in dose received 
by organs at risk (OAR) were calculated between dose distribution 2 and dose distribution 1. 
The expression (2) summarizes what has been here described. 
 
(2)                                                                    
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Where        is the difference in dose, received by OAR (in percentage, %, of irradiated 
volume for prostate patients and in cGy for HN patients since for these mean and maximum 
doses were evaluated),       is the OAR irradiated volume in dose distribution 2 (in % of 
irradiated volume, for prostate patients or cGy, for HN patients) and       is the OAR 
irradiated volume in dose distribution 1 (in % of irradiated volume or cGy).  
Differences in the Planning Target Volume (PTV) coverage with 95% of the prescribed dose 
(in cc) between the dose distribution 1 and dose distribution 2 were, likewise, compared. The 
expression (3) describes this is: 
 
(3)                                                                     
 
       is the difference in the volume of the PTV coverage with 95% (in cc),       is the 
volume of PTV coverage with 95% of the prescribed dose in the dose distribution 2 (in cc) 
and       is the volume of PTV coverage with 95% of the prescribed dose in the dose 
distribution 1 (in cc).  
Since there were differences in the OAR considered for treatment planning in the HN group, 
maximum and mean doses (cGy) were compared in these patients only for the spinal cord, 
since this is an organ commonly considered for all patients. For prostate patients, dose 
differences for the OAR were evaluated for bladder and rectum according to the following 
constraints: 50% of the bladder volume should only receive up to 70 Gy and 50%, 25% and 
5% of the rectal volume should be irradiated with no more than 60 Gy, 72 Gy and 74 Gy 
respectively. Differences between the final and initial dose distributions were calculated and 
the results were analyzed. Differences in the coverage of volumes irradiated with 95% of the 
dose were evaluated for both pathologies.  
For the analysis of the difference of the dose distribution values, either for the PTV coverage 
with 95% of the prescribed dose or for the aforementioned OAR assessment, a Wilcoxon test 
for paired samples was used. Statistical significance was considered with p<0,05. 
 
RESULTS 
CTDI 
Table 1 shows the values of CTDI, CTDI peripheral and CTDIw. Measurements of CTDIw for  
beam settings in the pelvis were 28.33, 28.45 and 26.44 mGy for 410 mm medium FOV, for 
M15F0, M15F1 and M10F1, respectively. For head, CTDIw measurement was 1,02 mGy. 
A total of 76 HN pre-treatment CBCT (range 9-13, mean 10,86 acquisitions/patient) and 17 
HN post-correction CBCT were performed. For prostate patients, 138 pre-treatment CBCT 
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Table1. Collimator and Filter cassettes, site and beam settings, FOV dimension and peripheral CTDI 
and weighted doses estimated for the clinical protocols adopted. 
  
(range 6-14, mean 9,86 acquisitions/patient) and 34 post-correction CBCT were undertaken. 
Consequently, the administered doses, considering the preset used for each treatment,  
ranged from 9,18mGy to 15,76mGy (mean 13,5mGy/patient) for HN and from 170,7mGy to 
528,8mGy (mean 337mGy/patient). 
 
Control Charts 
 Control charts for mean (fig. 2a, 2b and 2c) and SD (2d, 2e and 2f) are presented in figure 2 
for the initial phase on prostate treatments (respectively, for the LM, CC and AP axes). It is 
hence observable in the control charts for the mean (fig. 2a and 2c) that the control limits are 
never exceeded with the exception of the CC axis (fig. 2b), as the mean of the SetD for 
patient 21 is out of statistical control. For the initial phase of prostate treatment, TL are never 
exceeded in any case.  
By analyzing the charts for the SD of each patient in this phase, it is readily detectable that 
patients 2 and 16 are out of statistical control in the LM axis and that patients 2, 3 and 21 are 
also out of statistical control in the CC axis. However, control limits are never exceeded in 
the AP direction. 
Figure 3 displays the control charts for mean (Fig. 3a, 3b and 3c) and SD (Fig. 3d, 3e and 3f) 
in the boost phase of prostate treatment. Through analysis of these graphics, it is detectable 
that patients 10 and 16 have means overlapping to the superior control limits, namely in the 
LM and CC axes. For the charts considering the mean, patient 19 was observed to be out of 
the inferior TL in the LM axis but, however, not out of the inferior control limit. There is also a 
patient that exceeds the inferior control limit and the CC TL. On the AP axis, the control limits  
Collimator Cassettes/ 
Site (beam settings) FOV (mm) CTDI peripheral (mGy) CTDIw (mGy) 
Filter Cassettes 
M15F0 
Pelvis 
410 mm 34,1 28,33 
(120 kV/ 1040mAs) 
M15F1 
Pelvis 
410 mm 33,48 28,45 
(120kV/ 1664mAs) 
M10F1 
Pelvis 
410 mm 31,07 26,44 
(120kV/ 1664mAs) 
S10 F0 
Head 
270 mm 1,1 1,02 
(100kV/36,1mAs) 
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are never exceeded. Nevertheless, the superior TL is exceeded in the cases of patients 2, 3, 
7 and 21. It is evident that patients 2 and 3 are out of control limits on the LM and CC axes, 
respectively, on the SD charts. On the AP axis, there are no patients that exceed the 
aforementioned control limits.  
The control charts for the mean of the SetD of the initial phase in HN patients are displayed 
in figures 4a, 4b and 4c for the LM, CC and AP axes, respectively. It is observable that there 
are no points out of the control limits, except for the chart of the SetD in the AP axis, since 
the mean of the deviations in patient 12 is out of the inferior limit. After investigation of its 
causes, this discrepancy was attributed to the patient’s severe weight loss, with increasing 
SetD during the first phase of treatment. In this case, during the last week of the initial phase, 
daily CBCT became mandatory. As a correction strategy during the boost phase, a new 
dosimetric planning was performed including obviously a new immobilization mask and a 
second planning CT. In the control charts of the SD on the LM (4d), CC (4e) and AP (4f) 
directions, patients 12, 6 and 1, respectively, had SD that exceeded the control limits. 
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Through analyzing the control chart for the mean of the SetD during the boost phase (Fig. 
5a, 5b and 5c) in HN patients, it can be observed that the SD of patients 4 and 11 is out of 
control limits in the AP and LM axes, respectively. Also worthy of note are the mean of 
patient 4, which is very close to the inferior control limit of the chart in the CC axis, and the 
mean of the SetD of patient 8, which exceeds the superior TL but keeps within control limits 
in the CC axis. In the control charts of the SD (Fig. 5d, 5e and 5f) there are no patients out of 
statistical control. 
According to the results in the control charts, 6 prostate and 6 head and neck patients were 
selected for a new dosimetric distribution accounting for the setup errors on the isocenter 
position (distribution 2), with the intent of verifying what would have happened if these out-of-
tolerance SetD had not been corrected. This was done by comparing distribution 2 to the 
dose distribution approved at the treatment planning phase (initial distribution or distribution 
1), performed on the treatment planning computed tomography. 
It is important to note that the patients out of statistical control were found not to comply with 
the dietary recommendations, even though they did not have a filled rectum as observed on 
CBCT imaging. 
35 
 
 
 
Dose distributions 
Table 2 displays the result of        for the prostate patients. For this group, considered 
OAR were the rectum and the bladder and were evaluated according to aforementioned 
dose constraints. For patient 3, the prescribed dose was 65Gy, hence, bladder or rectal 
volumes irradiated with a dose equal or superior to 70Gy and 72Gy, respectively, were not 
considered. A negative value on the        reflects a decrease of the OAR irradiated volume 
in the dose distribution 2 which was performed with the observed setup errors, whereas a 
positive value represents an increase in the irradiated volume. 
With the exception of patient 3, an increase in the difference of irradiated rectum 
corresponds to a decrease in bladder volume and vice-versa in all patients. Differences in 
dose distributions for the irradiated bladder volume percentage range from -4,69% to 5,44% 
(in average -1,4%).  
It is noteworthy to state that, for 4 of the studied patients, a decrease of the bladder irradiated 
volume is observed in dose distribution 2, whereas an increase of bladder irradiated volume 
in dose distribution 2 happens in the other 2 patients. However, the bladder volume  
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percentage irradiated with a dose equal or superior to 70Gy on distribution 2 does not 
significantly differ from the initial one (p=0,232).  
 
Table 2. Difference in percentage of irradiated volume in bladder and rectum observed in the two dose 
distributions for prostate patients. 
      , Differences in volume of organ at risk (% irradiated volume) 
Patient Bladder ≥70Gy Rectum ≥60 Gy Rectum ≥72Gy Rectum ≥74Gy 
2 -3,97 9,81 1,61 0,26 
3 NA 2,55 NA NA 
7 -4,6 14,83 16,38 11,29 
10 1,22 -3,5 -1,72 -1,25 
16 -4,69 6,62 4,46 3,47 
19 5,44 -16,31 -12,48 -1,92 
21 -1,83 9,75 7,78 6,29 
Average, µ -1,4 3,4 2,7 3 
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On the other hand, differences in dose distribution for the irradiated rectum volume ranged 
from -16,32% to 16,38% (in average 3,4, 2,7 and 3 for the Rectum≥60 Gy, 72Gy and 74Gy, 
respectively). In this case, it was verified that 5 of 7 patients had an increase of irradiated 
rectum volume for the measured dose constraints. 
Nevertheless, the volume percentage of the irradiated rectal volume with a dose equal or 
superior to 60Gy, 72 Gy or 74 Gy on distribution 2 does not significantly differ from dose 
distribution 1 (p=0,199; p=0,232; p=0,232; respectively).  
The difference in volume (cc) of the PTV (1; 2 and 3) irradiated with 95% of the prescribed 
dose between the dose distribution 2 and 1 is shown in Table 3. This was not evaluated in 
the case of the PTV3 of patient 3, since he did not have a third phase of treatment. The 
negative values displayed on the table reflect a decrease in this difference. These 
differences range from -40,3cc to 2,8cc for PTV1; -22,3cc to -4cc for PTV2 and -8,1cc to -
2,7cc for PTV3. 
 
Table 3.       , difference in PTV volume (cc) irradiated with 95% of the prescribed dose as 
observed in the two dose distributions for prostate patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In all cases, distribution 2 demonstrates that there is a decrease in the volume irradiated with 
95% of the prescribed dose against the initial distribution (dose distribution 1). 
The median of the PTV1, PTV2 and PTV3 volumes irradiated with 95% of the prescribed 
dose for distribution 2 was significantly lower than on the initial distributions (p=0,009; 
p=0.009 and p=0,014; respectively). 
Table 4 displays the result of the differences of the maximum and mean doses on the spinal 
cord of HN patients between dose distribution 1 and 2. As stated earlier in other instances, a 
negative value for these differences reflects a decrease in the dose as observed on 
distribution 2. This was, however, not performed in the case of patient 6, since the spinal 
cord was not considered as an organ at risk for the initial distribution.  
      , Difference in irradiated PTV for prostate patients (in cc) 
Patient PTV 1 PTV 2 PTV3 
2 -11,37 -13,43 -5,19 
3 -40,3 -22,3 NA 
7 -14,1 -10,8 -4,4 
10 -2,8 -6,6 -3,6 
16 -4,8 -5,4 -4,1 
19 -15,4 -11,7 -8,1 
21 -4,4 -4 -2,7 
Average, µ -13,3 -10,6 -4,7 
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Three of the analyzed patients would have an inferior dose maximum if the SetD had not 
been corrected, however, two patients have an increase in this dose maximum. It is also 
observable that the mean dose on the spinal cord would increase only in one patient and 
would diminish in 4 other cases if the SetD had not been corrected. 
The median of the dose maximum on the spinal cord does not significantly differ between 
distributions 2 and 1(p=0,229). A similar observation was made for the median of the mean 
dose on the spinal cord (p=0,137). 
 
Table 4. Difference in percentage of spinal cord maximum and mean observed in two dose 
distributions for HN patients. 
 
Volume irradiated (in cc) 
Patient Spinal cord max 
Spinal cord 
mean 
1 86 21 
4 -103 -59 
6 NA NA 
8 -36,8 -17,3 
11 -66 -7 
12 64 -33 
 
The difference in volume (in cc) of both PTV1 and PTV2 irradiated with 95% of the 
prescribed dose between distribution 1 and 2 is presented on table 5. This difference was not 
assessed for patient 6, since in this case there was no second phase of treatment.  
The negative values on this table report a decrease in the volume of the PTV irradiated with 
95% of the prescribed dose between dose distribution 2 and 1, so a negative value implies 
that the volume covered with 95% of the dose was inferior in distribution 2.  
As can be seen, differences in these values range from -7,4cc to 3,3cc for PTV1 and from -
5,1cc to 0.8 cc for PTV2. 
For PTV1, in all cases, distribution 2 demonstrates a decrease in the volume irradiated with 
95% of the prescribed dose with the exception of patient 1. In the case of PTV2 results are 
similar, with a decrease in values for all patients except for patient 2, in whose case there is 
an increase in the volume of the PTV2 irradiated with 95% of the dose and for patient 12, for 
whom no difference can be noted. 
The median of the volume of PTV1 irradiated with 95% of the prescribed dose on distribution 
2 is significantly inferior to this value as verified on the initial distribution (p=0,0365). For the 
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PTV2, the median of the volume covered with 95% of the prescribed dose does not differ 
significantly between dose distributions (p=0,1425). 
 
Table 5. Difference in cc, on PTV 1 and 2 observed in two dose distribution for HN patients. 
Volume irradiated com 95% da dose prescrita 
(in cc) 
 Patient PTV 1 PTV 2 
1 2,5 0,8 
4 -3,4 -5,1 
6 3,3 NA 
8 -1,9 -2,2 
11 -4,7 -0,9 
12 -7,4 0 
Average, µ -1,9 -1,5 
 
DISCUSSION: 
 
The main purposes of the reported work were to quantify SetD during radiotherapy for 
prostate and head and neck (HN) pathologies, as measured with CBCT. Justification of 
CBCT doses administered to the patients was hence performed, verifying the eventual 
treatment benefit of this IGRT protocol by simulation of the SetD during radiotherapy in dose 
distributions. This allowed for predicting a situation in which these errors would not have 
been corrected. The adequacy of the imaging protocol for these pathologies was assessed. 
Finally, the identification of an optimal point between imaging dose and beam alignment error 
correction, which is a key issue in the precision of radiotherapy delivery, was also addressed.  
The TL for the initial prostate treatment phase, either for the mean or for the standard 
deviation, are never exceeded. This might result from the fact that every patient was carefully 
instructed about rectum and bladder preparation. It is noteworthy that the LM and CC TL set 
for the initial phase of the prostate should be rethought, since the mean values of the SetD of 
the sample set never exceed ± 0.3 cm. Patients were also instructed to repeat the 
preparation protocol again in case a rectal and/or bladder filling that differed from the 
planned one was observed on pre-treatment control imaging. Still it is important to state that 
the SD for the prostate patients was high, because even when the means of SetD are in 
control, most patients are out of statistical control in SD charts. This induced us to think 
about our methods and protocols. 
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The TL at the initial phase of HN treatment could also be reduced, since the mean of the 
SetD is never superior to ± 0,2 cm in the LM and CC directions. On the AP axis, the mean is 
always inferior to ±0,25cm.  
In view of the results observed on the control charts, it is clear that 29% and 25% of the 
sample set of patients with prostate tumours is out of statistical control on the initial and 
boost phases of treatment, respectively. In the case of the HN group, 43% of the sample set 
is out of statistical control, however, in the boost phase, this proportion is reduced to 33%. 
Through the simulation reported in this work, it was found that if the SetD had not been 
corrected, there would not be a significant difference on the median of the percentage of the 
irradiated volume of the OAR for prostate patients. Interestingly for PTV coverage with 95% 
of the prescribed dose, the opposite is observed, with a decrease of, in average 13,3 cc in 
PTV1, 10,6 cc in PTV2 and 4,7 cc in PTV3. This demonstrates a therapeutic gain through the 
use of verification imaging, even though we are increasing the delivered dose by 337 mGy 
(in average) with its use. This increment is obtained through ensuring that the planned dose 
is indeed administered on the target volume and that this volume is treated globally and 
reproducibly. 
Regarding the HN patients, there was no significant difference in median values of the mean 
dose delivered to the spinal cord after comparison of the aforementioned dose distributions. 
Yet, there is a significant decrease in PTV1 coverage with 95% of the prescribed dose when 
comparison of the distribution 1 with distribution 2 was undertaken, with an average of -1,9 
cc in loss. This difference was not observed for PTV2. It is thus clear that, from the 
therapeutic perspective, there is an increase in the therapeutic ratio from the increment of 
dose delivery of an average of 13,5 mGy/patient provoked by verification imaging, since the 
tumour control probability might again be affected by a decreased dose coverage of the 
target volume. 
Other positive aspects might be inferred from the reported observations, since the 
visualization of target volumes and surrounding structures allow for monitoring of the filling 
status of organs such as the bladder or the rectum. It is also possible to assess the status of 
the target volume itself, which might decrease, move and thus be altered during treatment. 
 
CONCLUSION: 
 
Even though this is a small series of patients, the reported work clearly states both the utility 
and feasibility of the IGRT protocol in view of the dose-benefit paradigm, with a solid 
justification of the dose increment delivery through the use of the CBCT imaging tool. Indeed, 
simulated data confirmed the point of using CBCT according to the described protocol. 
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In the future, studies should be made to allow for the CBCT dose to be accounted for in the 
treatment planning phase, even though there are difficulties in adding this dose to the 
prescribed one, as described by Murphy et al. [21] 
This work allowed for determination of aspects of our IGRT protocol that need to be 
rethought, namely on the TL. These must be chiefly re-assessed in the LM and CC axes 
during the first phase of treatment for prostate tumours, whereas for HN tumours this must 
be done for all axes. 
To conclude, the next steps in the adaptation of the IGRT protocol will be to study and 
recalculate the TL, just as defining the correct methodology to apply these in all cases. In the 
ever developing field of radiotherapy precision, adapting and revising these protocols, in light 
of new imaging tools, will bring clear gains in the treatment of patients with such a 
devastating disease as cancer proves to be. 
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ABSTRACT: 
 
BACKGROUND/PURPOSE: Radiotherapy precision is an important issue in current state of the 
art treatment methods. In order to ensure target volume coverage and organs at risk sparing, 
ensuring that radiation is delivered to intended targets is of utmost importance. Image-guided 
radiotherapy (IGRT) provides us with useful tools to address this problem. However, in order 
to allow for correct use of these technologies and ensuring proper treatment delivery 
methods, systematic and random errors need to be assessed and accounted for at the 
treatment planning and delivery stages. 
MATERIAL/METHODS: 21 patients (pts) undergoing prostate or head and neck (HN) 
radiotherapy at our department were randomly selected and underwent an IGRT protocol 
resorting to cone-beam computed tomography (CBCT) as the verification imaging technique. 
Setup error analysis was performed in order to evaluate systematic and random errors during 
treatment delivery in the cranio-caudal (CC), latero-medial (LM) and antero-posterior (AP) 
directions. 
RESULTS: Intrafraction movements do not increase during HN treatment except for the LM 
direction. In the case of the prostate group, the most increased systematic error values are 
observed in the AP direction. For the initial phase of HN treatment, ideal margins for PTV are 
2,1mm, 3,5mm and 2,1mm, in the LM, CC and AP directions respectively. For the boost 
phase, values thus calculated are 4,0 mm, 1,6 mm e 2,7 mm in the same order. In the 
prostate group, ideal margins of 4,8mm, 4,3mm and 5,4mm for the initial phase in the LM, 
CC and AP axes were calculated, whereas for the boost phase 5,7mm, 6,5mm e 8,0mm 
margins were obtained, considering the same order. 
CONCLUSIONS: Patient information on dietary requirements, rectal and bladder preparation 
should be stressed and informative methods revised. PTV margins used at our department 
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might be reduced for both phases of HN cancer treatment and for the initial prostate cancer 
treatment phase. However, margins applied at the treatment planning stage in the prostate 
boost phase need to be increased. 
Keywords: Setup Errors, Sistematic Error, Random Error and Isotropic Margins 
 
INTRODUCTION 
 
Precision is a key issue in current state of the art radiotherapy. In fact, as we moved from 2D 
to 3D imaging techniques and with the subsequent application of more refined radiotherapy 
technologies, such as Intensity Modulated Radiotherapy (IMRT) or stereotactic radiotherapy, 
ascertaining that radiation is delivered to the intended targets has become more important 
than ever. Indeed, radiation accuracy is logically coupled to an increase in tumour control 
probability and a concurrent decrease in treatment-related toxicity. However, the advent of 
such concepts, with a close conformity to the tumour progressively becoming the paradigm in 
this cancer treatment method, imposes treatment accuracy as a crucial aspect of modern 
radiotherapy. 1 
The ever evolving field of image-guided Radiotherapy (IGRT) provides us with the tools for 
bringing this important issue to new harbours. Indeed, this has been the focus of active 
research and development in recent years, with exciting new technologies being looked into 
and applied in numerous centers around the globe. One of these advents was the Cone 
Beam Computed Tomography (CBCT), which allowed us to perform computed tomography 
(CT) immediately before radiotherapy fractions.2-6 Thus, we are nowadays empowered with 
the means to compare, with nearly identical resources, patient data, obtained at the planning 
and treatment delivery stages, in a safe and effective way. This might allow us to reduce 
margins used for treatment planning, with a consequent decrease in toxicity, but still keeping 
treated volumes focused on the tumour and any of its microscopic extensions.7 
However, we still rely on guidelines yielded by key, world-class, institutes of reference. 
Although these guidelines provide crucial information that enables other departments to 
implement techniques in a somewhat faster way, it is important to study the impact of these 
new radiotherapy delivery methods, in order to provide patients with quality-assured and 
reliable treatments.8 Furthermore, people and technology differ between departments and 
guidelines implemented in a particular case might help, but they cannot replace data 
obtained locally, in the actual working conditions of a particular healthcare unit. 
The work hereby reported focused on quantifying the translational and rotational setup 
deviations, as well as quantifying the intrafraction movements and setup errors in head and 
neck (HN) and prostate cancer patients treated at our department. Its main purpose is, 
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therefore, to adapt our currently implemented IGRT protocol in light of this data. In order to 
tackle these issues, rotational and translational deviations were quantified for prostate and 
HN patients during treatment, resorting to CBCT as a way to detect differences during 
radiotherapy. In addition, the question of the direction with the most important amplitude of 
deviation is addressed, as is the eventual difference in systematic and random errors 
between the initial and boost phases, since these subjects might yield new paradigms at the 
radiotherapy planning stage. 
 
METHODS AND MATERIALS 
 
Patients 
From May 2011 to September 2011, patients with prostate and HN cancer undergoing 
radiotherapy at our department were randomly selected. This study included 21 patients, 19 
male and 2 female, with a mean age of 65 (range 36-79) years. Diagnoses were prostate 
cancer in 14 cases and HN cancer in the remaining 7 cases. For the HN patients, 2 were 
diagnosed with tumours of the tongue, 2 with oral cavity cancer and the remainder 3 cases 
had a diagnosis of glottis, parotid and cheek mucosa tumours. All prostate patients had an 
adenocarcinoma histology and all the HN patients had squamous cell carcinomas, except for 
the parotid case, in which an adenocarcinoma was confirmed. All the patients had localized 
tumours, with no clinical evidence of distant metastases. They all had Karnofsky indices that 
were superior to 70%. 
Regardless of the treatment technique, all patients underwent an IGRT protocol for 
verification of patient setup and treatment delivery conditions.  
All patients signed an informed consent. 
 
Patient Positioning 
All HN patients were set in a supine position, with their arms along the body, with both 
palmar regions touching the table. The MedTechTM (CVICO®) head and shoulder mask 
fixation system, as well as thermoplastic head and shoulder masks were used in HN 
patients, in order to immobilize the HN region during planning CT and all treatment sessions. 
A planning CT with 3mm slices was performed from the vertex of the skull to 3 cm bellow the 
xiphoid process. 
Prostate patients were set in a supine position using the Combi-FixTM (CVICO®) baseplate, 
which combines feet and knee support. Planning CT was acquired from the fourth lumbar 
vertebra to 3 cm below the tuberosity of the ischium.  For these patients, a bladder and 
rectum preparation was recommended: patients were asked to urinate and drink 250 mL of 
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water 30 minutes before treatment and planning CT and instructed to empty their rectums 2 
to 3 hours prior to treatment and planning CT. All patients underwent a dietary protocol in 
order to minimize bowel movements. 
 
CBCT scans and IGRT Protocol  
For each HN patient, CBCT was obtained with 100 kV, 361 mAs, 205º of gantry rotation, 
acquiring 361 frames. The prostate parameters for CBCT imaging were 120 kV, 1040 mAs, 
360º of gantry rotation and 650 frames were acquired. 
All setup errors were analyzed with the Elekta X-ray Volume image (XVI) software. 
Automatic-3D registration of the reference planning CT and CBCT scans was performed 
using the cross-relation algorithm provided in this Elekta software. In order to obtain setup 
errors, CBCT images were acquired according to our IGRT protocol, as described below. An 
automatic grey-value matching was performed for prostate patients and an automatic bone 
matching was obtained for HN patients. The HN alignment clip-box was defined to include all 
the PTV and surrounding bones, like vertebras and the base of skull, excluding chin. The 
prostate alignment clip-box was defined to include the whole PTV, surrounding tissues like 
the bladder and bones, such as the femoral heads. The rectal volume was excluded to the 
maximum possible extent. 
In order to assess patient positioning, a pre-treatment (pre-tt) CBCT acquisition was 
executed for all imaging verifications. A post-treatment (post-tt) acquisition was also obtained 
to evaluate treatment reproducibility. For every setup error correction, a post-correction  
acquisition was performed in order to confirm accurate positioning. 
The timing of acquisition was consecutive for the first four treatment fractions. An average of 
the setup errors was calculated for the first three fractions to allow for systematic error 
minimization and applied at the fourth fraction of treatment. Subsequently, verifications were 
scheduled on a weekly basis. 
During weekly verification, only setup errors were corrected, according to defined values. 
These were 3 mm for HN in all axes and for all treatment phases. For the prostate group, an 
action level (AL) values were defined for the first phase of treatment as 5 mm in the latero-
medial (LM) and cranio-caudal (CC) axes; 3 mm were defined in the antero-posterior (AP) 
direction. For the second and third treatment phases in the latter group, AL was defined as 3 
mm in all axes. 
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Table 1. HN Translational setup errors for the initial and boost phases of treatment. 
 
XVI quality assurance was carried out monthly by checking geometric accuracy, image 
quality and safety of the mechanical system. 
 
Setup error analysis  
Initially, the mean and standard deviation were calculated, for each patient. The group mean 
(M) is the mean of all means. The systematic error (∑) of setup positioning was defined as 
the variability of the mean and was calculated as the standard deviation of the individual 
means. The random error (σ) was defined as the root-mean-square of the individual standard 
deviation of setup error in each patient.9 Intrafraction movement was also calculated for both 
groups as the difference between the post-tt and pre-tt acquisitions. The Wilcoxon signed-
rank test was used to assess the differences in the pre-tt and post-tt translational and 
rotational setup errors. In order to assess intrafraction movement, a Mann-Whitney test was 
used to compare the means in the three axes. The Kruskal-Wallis one-way analysis of 
variance was used to test the differences in intrafraction movement during treatment. 
Statistical significance was considered when the p value was inferior to 0,05. 
 
RESULTS 
 
Twenty-one patients underwent CBCT scan for 7-17 fractions of their treatment, with a mean 
of 11 CBCT for HN patients and 10 CBCT for prostate patients. A total of 161 HN CBCT and 
294 prostate CBCT were acquired, including 214 pre-treatment CBCT in both pathologies, 51 
pre-correction CBCT and 190 post-treatment CBCT. 
  
HN translational setup errors 
  
M (mm) ∑ (mm) σ (mm) 
  
LM CC AP LM CC AP LM CC AP 
First treatment 
Phase 
Pre-treatment (N=56) -0,3 0,5 -0,1 1,2 1,0 1,8 0,8 1,5 1,1 
Post-correction (N=9) 0,3 0,5 -0,2 0,4 0,3 0,1 1,0 0,4 1,3 
Post-treatment (N=51) -0,4 0,0 -0,7 0,4 0,7 1,6 1,3 1,1 1,3 
Boost treatment 
phase 
 
Pre-treatment (N=20) 0,4 1,8 -0,9 1,7 1,8 2,2 0,9 1,1 1,0 
Post-correction (N=8) 0,3 -0,2 -1,1 1,1 1,1 1,1 0,4 0,5 0,5 
Post-treatment (N=17) 0,1 0,4 -0,6 0,6 1,4 1,3 0,8 0,7 0,2 
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Table 2. HN rotational setup errors for the initial and boost phases of treatment. 
 
Tables 1 and 2 summarize the translational and rotational setup errors, respectively. As can 
be observed, the M of the translational setup errors of the first phase of treatment is ranged 
between -0,7 and 0,5 mm, the range of ∑ is from 0,1 to 1,8 mm and the σ is ranged from 0,8 
to 1,3 mm. For the boost phase, a marked difference is observed, since the calculated M 
ranges from -1,1 to 1,8 mm and the ∑ is ranged from 0,6 to 2,2 mm. In this case, σ ranged 
from 0,2 to 1,1 mm. It is noteworthy that, for the initial phase of treatment, 72,1% of the pre-tt 
translational deviations on the LM direction in HN patients range from -2 to 2 mm. The same 
range is observed for 71,1% of the setup errors in the CC and for 67,3% in the AP axis. For 
the boost phase, this observation is also valid for 85% of the setup errors in the LM, for 45% 
in the CC and for 80% in the AP directions. 
For the initial phase of treatment, the M of the measured rotational setup errors is ranged 
from -2,6º e 1,1º, ∑ ranges from 0,3º to 5,3º and σ ranges between 0,1º and 1,4º. For the 
boost phase the interval of M ranges from 0º a 0,8º, ∑ ranges from 0,3º to 1,4º and σ ranges 
from 0,1º to 1,4º. 
The median of the post-tt translational setup errors is therefore superior to the median of the 
pre-tt setup errors in all axes, with the exception of the AP direction. (p value=0,0235 for the 
LM direction, p value= 0,0025 for the CC direction and p value= 0,3525 for AP direction). No 
significant difference in the rotational deviations was found when compared to the pre-tt 
setup errors. 
It was also observed that, in the case of intrafraction movement in these pathologies, there is 
a significant increase in the LM axis (p= 0,043), however, this is not observed for the other 
two axes, in which there is no significant difference. 
  
HN rotational setup errors 
  
M (º) ∑ (º) σ (º) 
  
LM CC AP LM CC AP LM CC AP 
First treatment 
Phase 
Pre-treatment (N=56) 1,1 -2,6 0,4 0,6 5,3 0,6 0,4 3,0 0,3 
Post-correction (N=9) 1,2 0,1 0,5 1,0 0,3 0,3 0,6 0,8 0,7 
 
Post-treatment (N=51) 1,0 -0,4 0,4 0,8 0,7 0,4 0,5 0,5 0,4 
Boost treatment 
phase 
 
Pre-treatment (N=20) 0,8 0,2 0,1 1,4 0,3 0,8 0,4 0,8 0,5 
Post-correction (N=8) 0,2 0,3 0,0 1,1 1,0 0,7 1,4 0,5 0,2 
Post-treatment (N=17) 0,7 0,2 0,2 1,1 0,7 1,1 0,1 0,5 0,6 
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 Table 3. Prostate translational setup errors for the initial and boost phases of treatment. 
 
Significant differences in the intrafraction movement were not observed during treatment for 
LM and CC direction (p= 0,146 and 0,1295, respectively). However it was found that 
intrafraction movement increases in the course of treatment for the AP axis (p=0,0265). The 
translational and rotational setup errors for the prostate groups are displayed on tables 3 and 
4, respectively. For the initial phase of treatment, M is ranged between -0,7 and 0,3 mm, ∑ 
between 0,4 and 1,5 mm and σ ranges from 0,4 to 2,8 mm. For the boost phase, M ranges 
from -0,2 to 1,3 mm, ∑ from 0,4 to 2,9 mm and σ ranges from 0,3 to 2,0  
mm. On the translational pre-tt setup errors in the LM direction in prostate patients, 82,8% of 
these are ranged between -3,5 and 3,5 mm; the same is observed for 88,4% of these in the 
90,6% of the pre-tt setup errors in the LM axis, for 95,3% in the CC axis and for 67,4% in the 
CC and 76,7% in the AP directions. In the boost phase, the same range was for the AP axis. 
No significant difference in the translational deviations was found when compared to the pre-
tt setup errors and for rotational CC axis deviations. However, an increase in post-tt  
deviations was noted for the LM and AP directions, when compared to pre-tt data  (p value= 
0,002 and 0,0 respectively). 
For the initial phase of treatment, the M of the measured rotational setup errors is ranged 
from -0,1º e 0,4º, ∑ ranged from 0,4º to 1,5º and σ ranges between 0,2º and 1º. For the boost 
phase the interval of M ranges from -0,3º a 0,6º, ∑ ranges from 0,4º to 1,6º and σ ranges 
from 0,0º to 1,1º. 
No significant differences were observed for the mean of the intrafraction movements, which 
were not demonstrated to increase during treatment of prostate cancer patients. 
  
Prostate translation error 
  
M (mm) ∑ (mm) σ (mm) 
  
LM CC AP LM CC AP LM CC AP 
First treatment 
Phase 
Pre-treatment (N=99) 0,3 0,2 -0,7 1,1 1,2 1,5 2,8 2,0 2,5 
Post-correction (N=27) 0,3 -0,1 -0,2 0,5 0,4 0,8 0,9 0,4 0,6 
Post-treatment (N=88) 0,0 0,1 -0,6 1,3 0,8 0,7 1,3 1,4 1,4 
Boost treatment 
phase 
 
Pre-treatment (N=39) -0,2 -0,5 1,3 1,9 2,0 2,9 1,4 2,0 1,2 
Post-correction (N=7) -0,1 -0,1 -0,4 0,6 0,4 0,7 0,6 0,4 0,4 
Post-treatment (N=34) -0,3 0,2 -0,2 1,2 1,0 0,8 1,0 0,3 0,4 
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Table 4. Prostate Rotational setup errors for the initial and boost phases of treatment. 
 
DISCUSSION/ CONCLUSION  
 
The hereby reported work focused on studying the random and systematic errors associated 
to treatment delivery at our department, aiming at adapting the currently implemented IGRT 
protocol and at revising the adopted margins in the treatment planning stage. 
It was thus possible to understand that the intrafraction movements, unexpectedly, do not 
increase during HN treatment except for the LM direction. In fact, side-effects kick in during 
treatment and, although they are tackled through supportive treatment, they still may worsen 
and would be expected to create patient instability. The aforementioned exception might be 
attributed to the shape of thermoplastic masks used at our department and this question 
should be addressed in future work. 
Future steps regarding this issue might revolve around the definition of rotational AL that, 
regardless of a previous guideline in the case of HN patients, should be addressed. This 
point is even more valid if we consider the CC direction, in which they are more severely 
altered. 
In the case of the studied prostate group, the most increased ∑ values are observed in the 
AP direction. This may logically be attributed to intestinal, rectal and bladder movement. 
Even though all patients were carefully instructed about the rectal preparation and received 
information on dietary requirements during treatment, compliance with these measures is 
poor in a major proportion of patients. Furthermore, this might be complicated by a degree of 
unpredictability in the outcome of such preparations. Nevertheless, new methods to increase 
awareness of these issues in patients undergoing radiotherapy should be investigated, 
namely resorting to audiovisual material, in order to generate a clear understanding of the 
benefits of these simple, yet very important measures. 
  
Prostate Rotational error 
   
  
M (mm) ∑ (mm) σ (mm) 
  
LM CC AP LM CC AP LM CC AP 
First treatment 
phase 
Pre-treatment (N=99) 0,1 0,1 -0,1 1,4 0,5 0,4 0,6 0,2 0,2 
Post-correction (N=27) 0,1 0,2 -0,1 1,5 0,7 0,4 0,9 0,5 0,2 
 
Post-treatment (N=88) 0,4 0,2 0,0 1,1 0,7 0,5 1,0 0,2 0,2 
Boost treatment 
phase 
Pre-treatment (N=39) 0,4 0,1 -0,1 1,5 0,6 0,4 1,0 0,6 0,3 
Post-correction (N=7) -0,2 0,1 -0,3 1,6 0,5 0,5 1,1 0,3 0,0 
 
Post-treatment (N=34) 0,6 0,3 -0,1 1,3 0,7 0,5 0,1 0,3 0,3 
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Moreover, the identification of systematic and random errors allow for calculation of PTV 
isotropic margins according to the formula devised by Van Herk et al. 20: 
M=2,5 ∑+ 0,7σ. 
For the initial phase of HN treatment, yielded values are 2,1mm, 3,5mm and 2,1mm, in the 
LM, CC and AP directions respectively. For the boost phase, values thus calculated are 4,0 
mm, 1,6 mm e 2,7 mm in the same order. This suggests that, at our department, currently 
used margins, which slightly exceed these limits, ensure adequate coverage of the PTV. 
In the case of prostate cancer treatment, in order to ensure PTV coverage with at least 95% 
of the prescribed dose, this formula generates margin values of 4,8mm, 4,3mm and 5,4mm 
for the initial phase in the LM, CC and AP axes respectively, whereas for the boost phase it 
yields 5,7mm, 6,5mm e 8,0mm, considering the same order. 
Unlike the previous observation, an increase in currently used margins seems to be 
mandatory to ensure a safe treatment delivery. This also suggests that the random and 
systematic errors increase during the boost phase, which might be explained by the onset or 
increase of radiotherapy side-effects in this phase in the studied cohort. A possible way to 
tackle this problem would be treatment replanning at the boost phase, resorting to a new 
planning CT. 
When these results are compared to the random and systematic errors reported by other 
authors13-19, it is verifiable that they are in the same order of magnitude, with the sole 
exception of the prostate boost phase, which further stresses the importance of addressing 
this problem. 
In conclusion, this study allowed for uncovering an eventual possibility of decreasing the PTV 
margins for HN cancer radiotherapy planning. It also showed that prostate margins might 
also be reduced during the first phase of treatment. In fact, a decrease in the irradiated 
volume, as defined in the ICRU 62 report 21, might account for less side-effects, with a 
consequent increase in patient stability and, more importantly, life-quality. These conclusions 
should, therefore, make way for new treatment delivery methods. Future steps should be 
made in order to minimize systematic and random errors associated to the boost phase in 
prostate patients, as to ensure more and more accuracy in radiotherapy and a consequent 
increment in the quality of treatment. 
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GENERAL CONCLUSION: 
The purpose of this study was to verify the feasibility of a previously devised IGRT protocol, 
as to adapt it to the observed reality at the department. 
In conclusion, every prostate patient received in average 337 mGy and every HN patient 
received in average 13.5 mGy derived from CBCT usage during their treatments. However, if 
the SetD had not been corrected, there would not be a significant difference on the irradiated 
volume of the OAR for prostate patients, as well as a decrease in PTV coverage. In the case 
of HN patients, the PTV coverage would have been decreased. For all these reasons, the 
outcome of treatment would have been greatly modified, with a probable decrease in both 
toxicity outcomes and tumour control. 
It was also observed that systematic errors increase during treatment for both pathologies. 
We should therefore rethink current strategies employed for informing patients about 
treatment preparation. Moreover, the data presented here supports that patients should be 
re-planned when they enter the boost phase. 
Future research should be aimed at accounting for the dose of CBCT during the treatment 
planning phase. Tolerance limits, as currently applied to prostate and HN patients, should 
also be recalculated, This is especially important for boost margins in the case of both 
pathologies. 
